Navigation Links
FDA Submission of B-R-A-H-M-S MR-proANP Kryptor
Date:3/6/2009

HENNIGSDORF, Germany, March 6 /PRNewswire/ -- B-R-A-H-M-S Aktiengesellschaft today announced it has submitted 510(k) file to the U.S. Food and Drug Administration (FDA) to market its patented B-R-A-H-M-S MR-proANP Kryptor Test.

Atrial Natriuretic Peptide (ANP) is predominantly produced in the atrium of the heart and comprises 98% of the natriuretic peptides in the circulation. ANP is involved in natriuresis, diuresis, vasodilation and cardiovascular homeostasis. Although this peptide is unstable, the B-R-A-H-M-S-assay detects the corresponding prohormone fragment: the Mid-Regional pro-Atrial Natriuretic Peptide (MR-proANP). In contrast to the mature peptide, MR-proANP is a stable and reliable surrogate measurement of atrial natriuretic peptide levels.

The clinical benefits of MR-proANP were analyzed within an international, multi-center, prospective, multi-marker trial called BACH (Biomarkers in Acute Congestive Heart Failure). Enrolling 1641 patients presenting with shortness of breath to participating emergency rooms the study demonstrated MR-proANP to be a highly useful marker for diagnosing congestive heart failure. Furthermore it provides additional information especially in diagnostically challenging subgroups such as obesity, higher age or renal dysfunction compared to routinely used markers.

First presented at the 2008 ESC Congress and subsequently at the 2008 AHA annual meeting, the results of the BACH-trial confirm the company's commitment to improving healthcare through highly effective biomarker tests and complement the success of the Procalcitonin Kryptor, the company's test for the diagnosis of severe bacterial infections, introduced in the U.S. in early 2008.

B-R-A-H-M-S is a global biotechnology company committed to improving healthcare through the discovery and development of new, innovative biomarkers for the diagnosis, treatment and therapeutic management of
'/>"/>

SOURCE B-R-A-H-M-S Aktiengesellschaft
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
2. MannKind Updates Status of NDA Submission for AFRESA
3. Kensey Nash Announces IDE Submission for Cartilage Repair Device
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
6. Alfacell Provides ONCONASE(R) NDA Submission Update
7. FDA Reviewing Biomoda Submission for Cancer Screening Study
8. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
9. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
10. Synbiotics Corporation Announces Human Submission for FluDetect(R)
11. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... ActivBiotics, Inc. today,announced the results of its ... rifalazil in the treatment of intermittent claudication,associated ... demonstrated,that treatment for two months with the ... significant improvement in walking distance,claudication onset times, ...
... Scientific Sessions ... 2007 in Orlando, Florida, ... ) today announced the successful completion,of its Phase 2b trial ... vaccine being,developed to treat nicotine addiction and prevent smoking relapse. ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
(Date:7/13/2014)... Nature Genetics identifies a novel genetic and ... esophagitis (EoE), opening up potential new therapeutic strategies ... , EoE is a chronic inflammatory disorder of ... hypersensitivity to certain foods and an over-accumulation in ... (part of the body,s immune system). EoE can ...
(Date:7/13/2014)... North American water storage systems market is estimated to grow ... at a CAGR of 21.0%, from 2013 to 2018. The ... in North America. The U.S. is experiencing high growth on ... and collection, and the increased spending on modernization and upgradation ... rate in Canada, and is rising at a rapid pace ...
(Date:7/13/2014)... July 13, 2014 According to ... and Computing Market by Component (processor, GPU, DSP, ... MDA, Medical), and Geography - Forecast and Analysis ... Mobile Processing & Computing Market is expected to ... CAGR of 20.75% from 2014 to 2020. , ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its ... beautiful. Recently, the company has announced its new selection ... more, all these outfits are available at discounted prices ... the supplier is now offering similar discounts for many ... has many other designs for sale, including flower girl ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2
... Gardner HealthDay Reporter , TUESDAY, Aug. 31 (HealthDay ... a strong policy statement directed toward pediatricians, parents and the ... are getting about sex from television, the Internet and other ... Media , was published online Aug. 30 and in the ...
... the National Institutes of Health and University of Chicago ... mice reduces the severity of skin and soft-tissue damage ... Staphylococcus aureus infections in the United States. By ... found they could greatly reduce the damaging effects of ...
... lawsuit about gay marriage, the talk at some point turns ... parents? Will their children whether adopted, conceived with the ... relationship adjust, adapt and succeed in a world dominated ... giving them, and come dressed in anecdotes and colored by ...
... (August 31, 2010) A new study ... Massachusetts General Hospital (MGH) suggests that S-Adenosyl Methionine ... effective, relatively well-tolerated, adjunctive treatment for adults with ... their treatment with antidepressant medication. This first-of-its-kind ...
... vaccination of healthcare personnel is a professional and ... regarding vaccination should not be tolerated, according to ... for Healthcare Epidemiology of America (SHEA). The paper, ... Healthcare Epidemiology journal and endorsed by the ...
... OAK BROOK, Ill. A study of triathletes published in ... reveals that the heart adapts to triathlon training by working ... first study using MRI to investigate effects of triathlon training ... associate professor at the University of Erlangen-Nuremberg in Erlangen, Germany. ...
Cached Medicine News:Health News:U.S. Pediatricians Decry Media's Portrayal of Sex 2Health News:U.S. Pediatricians Decry Media's Portrayal of Sex 3Health News:Treatment for S. aureus skin infection works in mouse model 2Health News:Treatment for S. aureus skin infection works in mouse model 3Health News:Children raised by gay couples show good progress through school 2Health News:Children raised by gay couples show good progress through school 3Health News:Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders 2Health News:Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders 3Health News:Nation's leading ID experts call for mandatory flu vaccine for all health-care personnel 2Health News:Combining resistance and endurance training best for heart health 2
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
Medicine Products: